Status:
TERMINATED
A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
Lead Sponsor:
Shire
Conditions:
Gaucher Disease
Eligibility:
All Genders
Brief Summary
The main aim of this study is to describe the safety profile of velaglucerase alfa (VPRIV) in participants with Gaucher disease type 1. Participants will be transitioning from other enzyme replacement...
Eligibility Criteria
Inclusion
- Participant with GD1 currently being treated with an ERT/SRT other than VPRIV for at least 6 months before baseline enrolment; or participant previously treated with another ERT/ SRT for at least 6 months prior to transitioning to VPRIV..
- Participant or legally authorized representative has provided written informed consent.
Exclusion
- In the opinion of the investigator, participant is at high risk of non-compliance.
- In the opinion of the investigator, participant is unsuitable in any other way to participate in this study.
- Participant is pregnant.
Key Trial Info
Start Date :
September 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 17 2021
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04094181
Start Date
September 19 2019
End Date
November 17 2021
Last Update
February 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta/Medical Genetics Clinic
Edmonton, Alberta, Canada, T6G 2H7